{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,11]],"date-time":"2026-03-11T13:06:22Z","timestamp":1773234382703,"version":"3.50.1"},"reference-count":15,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[1997,1,1]],"date-time":"1997-01-01T00:00:00Z","timestamp":852076800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Clin Rheumatol"],"published-print":{"date-parts":[[1997,1]]},"DOI":"10.1007\/bf02238770","type":"journal-article","created":{"date-parts":[[2005,11,14]],"date-time":"2005-11-14T16:35:09Z","timestamp":1131986109000},"page":"93-95","source":"Crossref","is-referenced-by-count":17,"title":["Retrobulbar optic neuritis after pamidronate administration in a patient with a history of cutaneous porphyria"],"prefix":"10.1007","volume":"16","author":[{"given":"J. M.","family":"Des Grottes","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.","family":"Schrooyen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J. C.","family":"Dumon","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J. J.","family":"Body","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"BF02238770_CR1","doi-asserted-by":"crossref","first-page":"624","DOI":"10.1097\/00001622-199208000-00005","volume":"4","author":"JJ Body","year":"1992","unstructured":"Body JJ. Bone metastases and tumor-induced hypercalcemia. Current Opinion in Oncology 1992;4:624\u201331.","journal-title":"Current Opinion in Oncology"},{"key":"BF02238770_CR2","doi-asserted-by":"crossref","first-page":"S15","DOI":"10.1007\/BF01623222","volume":"2","author":"H Fleisch","year":"1993","unstructured":"Fleisch H. New bisphosphonates in osteoporosis. Osteoporosis Int 1993;2:S15\u201322.","journal-title":"Osteoporosis Int"},{"key":"BF02238770_CR3","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1007\/BF01623227","volume":"4","author":"D Thi\u00e9baud","year":"1994","unstructured":"Thi\u00e9baud D, Burckhardt P, Melchior J, Eckert P, Jacquet AF, Schnyder P, Gobelet C. Two years' effectiveness of intravenous pamidronate (APD) versus oral fluoride for osteoporosis occurring in the postmenopause. Osteoporosis Int 1994;4:76\u201383.","journal-title":"Osteoporosis Int"},{"key":"BF02238770_CR4","unstructured":"Stettler E.R. Central epidemiology and drug safety. Ciba, Basle, Switzerland: personal communication."},{"key":"BF02238770_CR5","first-page":"352","volume-title":"Hematology: Basic principles and practice","author":"RJ Desnick","year":"1991","unstructured":"Desnick RJ, Anderson KE. Heme biosynthesis and its disorders: the porphyrias and sideroblastic anemias. In: Hematology: Basic principles and practice. Hoffman R, Benz EJ Jr, Shattil SJ, Furie B, Cohen HJ, eds. Churchill Livingstone, New York 1991, Chap. 30, 352\u2013357"},{"key":"BF02238770_CR6","doi-asserted-by":"crossref","first-page":"580","DOI":"10.1001\/archopht.1971.00990050582010","volume":"85","author":"D Sevel","year":"1971","unstructured":"Sevel D, Burger D. Ocular involvement in cutaneous porphyria. Arch Ophtal 1971;85:580\u20135.","journal-title":"Arch Ophtal"},{"key":"BF02238770_CR7","unstructured":"Wood AJ. Adverse reactions to drugs. In Harrison's principles of internal medicine, 13th edition Editors, K.J. Isselbacher et al., McGraw-Hill Inc 1994, Chap. 67, 405\u201312."},{"key":"BF02238770_CR8","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1093\/oxfordjournals.annonc.a058841","volume":"5","author":"JJ Body","year":"1994","unstructured":"Body JJ, Dumon JC. Treatment of tumor-induced hypercalcaemia with the bisphosphonate pamidronate: Dose-response relationship and influence of the tumour type. Ann Oncol 1994;5:359\u201363.","journal-title":"Ann Oncol"},{"key":"BF02238770_CR9","doi-asserted-by":"crossref","first-page":"289","DOI":"10.2165\/00003495-199141020-00009","volume":"41","author":"A Fitton","year":"1991","unstructured":"Fitton A, Mc. Tavish D. Pamidronate: a review of its pharmacological properties and therapeutic efficacy in resorptive bone disease. Drugs 1991;41:289\u2013318.","journal-title":"Drugs"},{"key":"BF02238770_CR10","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1016\/S0002-9394(14)72902-2","volume":"118","author":"V Macarol","year":"1994","unstructured":"Macarol V, Fraundfelder FT. Pamidronate disodium and possible ocular adverse drug reactions. Am J Ophthalmol 1994;118:220\u201324.","journal-title":"Am J Ophthalmol"},{"key":"BF02238770_CR11","doi-asserted-by":"crossref","first-page":"436","DOI":"10.1016\/0140-6736(93)93029-Z","volume":"341","author":"ES Siris","year":"1993","unstructured":"Siris ES. Bisphosphoates and iritis. Lancet 1993;341:436\u201337.","journal-title":"Lancet"},{"key":"BF02238770_CR12","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/1043-4666(92)90028-P","volume":"4","author":"D Wakefield","year":"1992","unstructured":"Wakefield D, Lloyd A. The role of cytokines in the pathogenesis of inflammatory eye disease. Cytokine 1992;4:1\u20135.","journal-title":"Cytokine"},{"key":"BF02238770_CR13","doi-asserted-by":"crossref","first-page":"956","DOI":"10.1002\/jbmr.5650100617","volume":"10","author":"DH Schweitzer","year":"1995","unstructured":"Schweitzer DH, Oostendorp-Van de Ruit M, Van der Pluijm G, L\u00f6wik CWGM, Papapoulos SE. Interleukin-6 and the acute phase response during treatment of patients with Paget's disease with the nitrogen-containing bisphosphonate dimethylaminohydroxypropylidene bisphosphonate. J Bone Miner Res 1995;10:956\u201362.","journal-title":"J Bone Miner Res"},{"key":"BF02238770_CR14","unstructured":"Sauty A, Pechertorfer M, Fioroni P, Juillerat L, Leuenberger Ph, Burckhardt P, Thi\u00e9baud D. Serum levels of TNF \u03b1 and IL-6 in patients treated by Pamidronate, Clodronate and BM 21.0955. Bone Miner 1994;25 (Suppl.1):S69."},{"key":"BF02238770_CR15","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1016\/8756-3282(94)90899-0","volume":"15","author":"MB Oliveri","year":"1994","unstructured":"Oliveri MB, Mautalen C, Mega M, Rossi E. Congenital erythropoietic porphyria \u2014 Skeletal manifestations and effects of pamidronate treatment. Bone 1994;15:101\u20134.","journal-title":"Bone"}],"container-title":["Clinical Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/BF02238770.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/BF02238770\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/BF02238770","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,5,15]],"date-time":"2019-05-15T17:13:00Z","timestamp":1557940380000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/BF02238770"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[1997,1]]},"references-count":15,"journal-issue":{"issue":"1","published-print":{"date-parts":[[1997,1]]}},"alternative-id":["BF02238770"],"URL":"https:\/\/doi.org\/10.1007\/bf02238770","relation":{},"ISSN":["0770-3198","1434-9949"],"issn-type":[{"value":"0770-3198","type":"print"},{"value":"1434-9949","type":"electronic"}],"subject":[],"published":{"date-parts":[[1997,1]]}}}